Sanofi Falls After Breast Cancer Drug Fails in Trial
This article is for subscribers only.
Sanofi-Aventis SA, the French drugmaker trying to take over Genzyme Corp. of the U.S., fell the most in six months after saying one of its most promising experimental drugs failed in a key study in breast cancer.
Sanofi’s BSI-201, obtained with the June 2009 purchase of San Francisco-based BiPar Sciences Inc., didn’t lengthen overall survival or slow the disease in women with a certain type an aggressive, hard-to-treat tumor, Sanofi said in a statement yesterday. The outcome was surprising because results from an earlier-stage trial had been “spectacular,” said Eric Le Berrigaud, an analyst at Raymond James in Paris.